Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Alnylam Pharmaceuticals ALNY -3.78% Get Free Report has outperformed the market over the past 15 years by 8.52% on an ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

President Trump's potential new tariffs on medicines raise concerns among investors, triggering declines in pharmaceutical ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...